Exhibit 10.3
CONSULTING AGREEMENT
THIS CONSULTING AGREEMENT (the “Agreement”), effective June 7, 2023 (the “Effective Date”), is entered into between Cue Biopharma, Inc., a Delaware corporation having an address of 40 Guest Street, Boston, Massachusetts 02135 (the “Company”), and Peter A Kiener, D.Phil, having an address of [**].
INTRODUCTION
The Company desires to contract with Consultant to provide certain services, and Consultant is willing to provide such services, all in accordance with and pursuant to the terms and conditions set forth in this Agreement. In consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which the parties acknowledge, the parties agree as follows:
Exhibit A.
1
ActiveUS 196747893v.4
2
ActiveUS 196747893v.4
(iv) which are conceived, made or reduced to practice during the Term of this Agreement and relate to the Company’s or its Affiliates’ then current or anticipated products or services, in each case whether in preliminary or final form and on whatever media rendered, together with any reports, drawings, plans, diagrams or other documents comprising or containing any of the foregoing in whatever media (all of the foregoing, collectively, “Work Product”) will be deemed work made for hire and made in the course of Services rendered under this Agreement and will be the exclusive property of the Company. To the extent that title of such Work Product does not vest in the Company by operation of law, Consultant hereby irrevocably transfers and assigns to the Company in perpetuity all worldwide right, title and interest in and to the Work Product and to any and all intellectual property rights relating thereto, including, without limitation, all patent rights, copyrights, trade secrets and other intellectual property rights. Consultant will promptly disclose all Work Product to the Company and execute and deliver to the Company all documents requested by the Company to evidence its ownership of the Work Product or as reasonably required by the Company to obtain and maintain patent, copyright, or any other intellectual property rights in the Work Product and to maintain and enforce the Company’s proprietary rights in the Work Product.
3
ActiveUS 196747893v.4
4
ActiveUS 196747893v.4
[Signature Page Follows]
5
ActiveUS 196747893v.4
IN WITNESS WHEREOF, the parties have executed this Agreement to be effective as of the day and year set forth above.
THE COMPANY
Cue Biopharma, Inc.
/s/ Daniel Passeri
Name: Daniel Passeri Title: CEO
CONSULTANT
/s/ Peter A. Kiener
Name: Peter A. Kiener, D.Phil
Notice Address:
[**]
EXHIBIT A TO CONSULTING AGREEMENT
SERVICES:
Consultant will serve as the Chairman of the Company’s Science and Technology Committee and will provide services relating generally to the Company’s research and development of pre- clinical and clinical candidates, regulatory strategies, evaluation of therapeutics, biomarkers, and other technologies that enhance Cue Biopharma’s platform development. Consultant will work with senior leadership to develop objectives and action plans designed to accomplish the Company’s strategic objectives.
COMPENSATION: